Verastem’s KRAS inhibitor shows early promise in pancreatic cancer
🤖 AI-generated content — The title and summary were produced automatically by artificial intelligence, without human editorial review.
Verastem Oncology reported encouraging early results for its KRAS G12D inhibitor, which is being studied in more than 200 patients with advanced solid tumors, including metastatic pancreatic ductal adenocarcinoma and non-small cell lung cancer.
Continue in the app — vote & join in ➔Source: STAT News · via ahirlevel.hu